Rafael Fonseca, MD
Mayo Clinic Scottsdale
Interview Date: May 22, 2019
The cost of healthcare is on the minds of every stakeholder including patients, provider and payers, especially when it comes to cancer treatment. Dr. Rafael Fonseca joins Myeloma Crowd Radio to share his insights about the complexity of myeloma, factors that impact the development of innovation in myeloma and the focus on getting the proper care to patients as other economic interests are balanced in the process. Dr. Fonseca addresses what is sometimes called "STEP therapy" and how costs issues may need to be balanced with the wholistic factors of great care.
Thanks to our episode sponsor
Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center, Director for Innovation and Transformational Relationships, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. Dr. Fonseca’s practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its effort to understand the disease and its impact on patients. In his laboratory, Dr. Fonseca has led his team of researchers in concentrating on the genetic nature of the clonal cells of plasma cell disorders. He is also interested in myeloma bone disease, prognostic markers and development of new therapies. Throughout his training and career, Dr. Fonseca has received numerous awards and honors, including the Young Investigator Award in Hematology (Celgene – Achievement Awards for Clinical Research in Hematology), the Damon Runyon-Walter Winchell Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr. Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia and Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund, for which he also serves as a clinical investigator. Dr. Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He is a frequent reviewer of grants and sits on the SPORE grant review panel. He has given many national and international presentations as a visiting professor and has authored more than 300 articles, book chapters, editorials, abstracts, and letters.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113
Support@healthtree.org
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.